References
- Agrawal U , Chashoo G , Sharma PR , et al. (2015). Tailored polymer-lipid hybrid nanoparticles for the delivery of drug conjugate: dual strategy for brain targeting. Colloids Surf B Biointerfaces 126: 414–25.
- Ahmed HH , Galal AF , Shalby AB , et al. (2018). Improving anti-cancer potentiality and bioavailability of gallic acid by designing polymeric nanocomposite formulation. Asian Pac J Cancer Prev 19: 3137–46.
- Anez-Bustillos L , Dao DT , Baker MA , et al. (2016). Intravenous fat emulsion formulations for the adult and pediatric patient: understanding the differences. Nutr Clin Pract 31: 596–609.
- Bernardi DS , Pereira TA , Maciel NR , et al. (2011). Formation and stability of oil-in-water nanoemulsions containing rice bran oil: in vitro and in vivo assessments. J Nanobiotechnol 9: 44.
- Carpentier YA , Simoens C , Siderova V , et al. (1997). Recent developments in lipid emulsions: relevance to intensive care. Nutrition 13: 73s–8s.
- Doenicke A , Roizen MF , Hoernecke R , et al. (1997). Haemolysis after etomidate: comparison of propylene glycol and lipid formulations. Br J Anaesth 79: 386–8.
- Doenicke AW , Roizen MF , Hoernecke R , et al. (1999). Solvent for etomidate may cause pain and adverse effects. Br J Anaesth 83: 464–6.
- Dong W , Zhang L , Niu Y , et al. (2013). A stable and practical etoposide-containing intravenous long-/medium-chain triglycerides-based lipid emulsion formulation: pharmacokinetics, biodistribution, toxicity, and antitumor efficacy. Expert Opin Drug Deliv 10: 559–71.
- Elmowafy M , Alruwaili NK , Shalaby K , et al. (2020). Long-acting paliperidone parenteral formulations based on polycaprolactone nanoparticles; the influence of stabilizer and chitosan on in vitro release, protein adsorption, and cytotoxicity. Pharmaceutics 12: 160.
- Erdoes G , Basciani RM , Eberle B. (2014). Etomidate–a review of robust evidence for its use in various clinical scenarios. Acta Anaesthesiol Scand 58: 380–9.
- Forman SA , Warner DS. (2011). Clinical and molecular pharmacology of etomidate. Anesthesiology 114: 695–707.
- Ganzberg S. (2017). The FDA warning on anesthesia drugs. Anesth Prog 64: 57–8.
- Gill RS , Scott RP. (1992). Etomidate shortens the onset time of neuromuscular block. Br J Anaesth 69: 444–6.
- Gou J , Chao Y , Liang Y , et al. (2016). Humid heat autoclaving of hybrid nanoparticles achieved by decreased nanoparticle concentration and improved nanoparticle stability using medium chain triglycerides as a modifier. Pharm Res 33: 2140–51.
- Gou J , Feng S , Liang Y , et al. (2017). Polyester-solid lipid mixed nanoparticles with improved stability in gastro-intestinal tract facilitated oral delivery of larotaxel. Mol. Pharmaceutics 14: 3750–61.
- Janssen PA , Niemegeers CJ , Marsboom RP. (1975). Etomidate, a potent non-barbiturate hypnotic. Intravenous etomidate in mice, rats, guinea-pigs, rabbits and dogs. Arch Int Pharmacodyn Ther 214: 92–132.
- Latson TW , McCarroll SM , Mirhej MA , et al. (1992). Effects of three anesthetic induction techniques on heart rate variability. J Clin Anesth 4: 265–76.
- Li Y , Jin W , Yan H , et al. (2013). Development of intravenous lipid emulsion of vinorelbine based on drug-phospholipid complex technique. Int J Pharm 454: 472–7.
- Lin Y , Pan Y , Shi Y , et al. (2012). Delivery of large molecules via poly(butyl cyanoacrylate) nanoparticles into the injured rat brain. Nanotechnology 23: 165101.
- Luo L , Chen Q , Wei N , et al. (2019). The modulation of drug-loading stability within lipid membranes via medium chain triglycerides incorporation. Int J Pharm 566: 371–82.
- Meuldermans WE , Heykants JJ (1976). The plasma protein binding and distribution of etomidate in dog, rat and human blood. Arch Int Pharmacodyn Ther 221: 150–62.
- Moghimi SM , Szebeni J. (2003). Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 42: 463–78.
- Moss E , Powell D , Gibson RM , et al. (1979). Effect of etomidate on intracranial pressure and cerebral perfusion pressure. Br J Anaesth 51: 347–52.
- Powell KC , Damitz R , Chauhan A. (2017). Relating emulsion stability to interfacial properties for pharmaceutical emulsions stabilized by Pluronic F68 surfactant. Int J Pharm 521: 8–18.
- Raman M , Almutairdi A , Mulesa L , et al. (2017). Parenteral nutrition and lipids. Nutrients 9: 388.
- Salmela L and Washington C. (2014). A continuous flow method for estimation of drug release rates from emulsion formulations. Int J Pharm 472: 276–81.
- Shi S , Chen H , Lin X , et al. (2010). Pharmacokinetics, tissue distribution and safety of cinnarizine delivered in lipid emulsion. Int J Pharm 383: 264–70.
- Ton MN , Chang C , Carpentier YA , et al. (2005). In vivo and in vitro properties of an intravenous lipid emulsion containing only medium chain and fish oil triglycerides. Clin Nutr 24: 492–501.
- Vanlersberghe C , Camu F. (2008). Etomidate and other non-barbiturates. Handb Exp Pharmacol 182: 267–82.
- Wang B , Tian H and Xiang D. (2020). Stabilizing the oil-in-water emulsions using the mixtures of dendrobium officinale polysaccharides and gum arabic or propylene glycol alginate.Molecules,25:759.
- Weng D , Huang M , Jiang R , et al. (2013). Clinical study of etomidate emulsion combined with remifentanil in general anesthesia.Drug Des Devel Ther 7:771–6.
- Wu W , Wang Y , Que L. (2006). Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system.Eur J Pharm Biopharm 63:288–94.
- Xiao K , Li Y , Luo J , et al. (2011). The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles.Biomaterials 32:3435–46.
- Zhang K , Lv S , Li X , et al. (2013). Preparation, characterization, and in vivo pharmacokinetics of nanostructured lipid carriers loaded with oleanolic acid and gentiopicrin.Int J Nanomedicine 8:3227–39.